Allay Therapeutics

Last week, Allay Therapeutics was pleased to participate in the Controlled Release Society (CRS) Singapore meeting, hosted by National University Health System. Koon Kiat Teu and the team – which included James Su, PhD, Nurfatin Samsudin, Daniel Seet, Darryl Lim, Sze Hwee Tan, Wei Li LEE, Ee Theng Ng and Alicia Ng – shared insights into our ultra-sustained analgesic product pipeline.?? ? We had the opportunity to highlight ATX101, our lead candidate designed to provide non-opioid pain relief from a single application, and showcase the controlled drug release technology that makes it possible.? ? Engaging with industry leaders on the future of drug delivery in post-surgical pain management is critical to advancing solutions that improve recovery and surgical outcomes. Thank you to our hosts and fellow attendees for the insightful discussions and collaboration.? ? Learn more about our pipeline: https://lnkd.in/eaVReUMz? #AllayTherapeutics #PainManagement #Orthopedics #DrugDelivery #Biotech?

BREAKING NEWS: Allay announces first patient dosed phase 2b registration trial of ATX101, marking a significant step forward on our path to changing the paradigm of postoperative pain management.? ? Learn more: https://lnkd.in/eYQ_S3az

Meet James Su, PhD, Senior Director of Corporate Development & Strategy at Allay Therapeutics.? With an extensive background in sustained drug delivery technologies across various therapeutic areas—including intra-articular, ophthalmic, gastrointestinal, and cardiovascular applications—James has become a strategic leader in Allay's growth and innovation.? James’ experience spans roles as a Strategy Advisor at the Center for Healthcare Innovation and a Technical Consultant at The Foundry, where he honed his expertise in collaborating and mentoring teams in breakthrough drug delivery solutions. James is a driven team player, bringing an entrepreneurial spirit to every project. His insights and expertise are pivotal as Allay continues to redefine pain management for post-surgical recovery. Learn more about our team here: https://lnkd.in/e7maqcWW??

Congratulations to Vertex Pharmaceuticals on the FDA approval of Journavx, with broad label to treat moderate-to-severe acute pain in adults, representing the first new drug class for acute pain in more than 20 years.? ?? We’re excited to see a new non-opioid pain management drug product now available for patients and providers.? ?? #PainManagement #Biotech?

We’re thrilled to announce that Allay will be attending #JPM25, joining the biotech community in San Francisco to discuss our latest innovations in non-opioid pain management. We look forward to engaging with industry leaders, sharing our vision for a future with sustained pain relief solutions, and connecting with potential partners. See you there! #JPM2025 #AllayTherapeutics #Biotech #PainManagement #Orthopedics?

As we reflect on 2024, we are incredibly grateful for the dedication of our team, the trust of our partners, and the support of our community. Together, we’ve reached new milestones in pain management, deepened our impact in post-surgical care, and moved closer to transforming recovery for patients. This holiday season, we want to thank everyone who has been part of our journey—our team, partners, and community. Here’s to a bright new year filled with health, innovation, and continued progress toward our mission. Happy holidays from Allay Therapeutics! #AllayTherapeutics #TeamAllay #Biotech

As Chief Medical Officer of Allay Therapeutics, David Hewitt, has been a visionary force in advancing clinical development in the pain management field.? With over two decades of experience, David brings a unique background that combines neurology expertise and an impressive track record in pharmaceutical clinical development. His work spans roles from Senior VP at Nura Bio to pivotal leadership in neuroscience and pain management at Syneos Health, Karuna Therapeutics, and Merck. Among his notable accomplishments, David led the pediatric migraine program that achieved FDA approval for Maxalt and contributed to the innovative drug-device system, Ionsys, for postoperative pain. His dedication to pioneering therapies that meaningfully impact patients’ lives is central to Allay’s mission to transform pain care. Learn more about our team here: https://lnkd.in/eF4k62RZ

As Allay’s clinical program advances, we recently hosted an Investigator Meeting for our upcoming Phase 2B study on ATX 101, our lead candidate in post-surgical pain relief. Designed to address the challenges of sustained, non-opioid analgesia, ATX 101 supports faster recovery times and less dependence on traditional pain management methods. This meeting wouldn’t have been possible without our incredible clinical team, whose expertise and commitment continue to drive Allay’s progress. We appreciate your dedication to improving patient outcomes and advancing innovative solutions in pain care. Learn more about our pipeline here: www.allaytx.com/pipeline #AllayTherapeutics #PainManagement #Orthopedics

We’re proud to announce that the U.S. FDA has granted Breakthrough Therapy designation (BTD) for ATX101, our investigational treatment for post-surgical pain following total knee replacement (TKA) surgeries. This news highlights the urgent need for non-opioid alternatives in managing post-surgical pain and the potential of ATX101 to provide extended pain relief, limiting opioid use and associated side effects.? ? This designation is supported by promising results from a Phase 2 dose-ranging trial, which demonstrated that ATX101 delivers up to 4 weeks of sustained pain relief, as well as clinically meaningful?improvements in functional activity and patient satisfaction. ? We’re looking forward to progressing to?the registrational?Phase 2B trial and working closely with the FDA to advance the development of ATX101 to patients in need. ? Read more in today’s release: https://lnkd.in/eYQ_S3az

Our inaugural?Portfolio Day?brought together our Board, portfolio companies, and partners for an inspiring day of networking, insightful discussions, and shared learnings?on building global life science companies. This milestone event capped off a year of?forging new connections, deepening partnerships, and driving our mission to advance health impact. We’re excited to continue building momentum with our incredible community! #ClavystBioConnects #Innovation #HealthImpact Accelerator Life Science Partners Allay Therapeutics Automera Droia Ventures Engine Biosciences Hummingbird Bioscience Leyden Labs Lightstone Ventures MediSix Therapeutics NSG BioLabs Nuevocor Paratus Sciences Polaris Partners Quilt Sunbird Bio Evotec BRIDGEs #65LAB